- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
AngioDynamics Inc(ANGO)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ANGO
11/13/2026: ANGO (1-star) is currently NOT-A-BUY. Pass it for now.
AngioDynamics Inc is a small-cap medical technology company specializing in minimally invasive devices for vascular interventions and cancer treatments. Its primary business strengths include robust double-digit sales growth in advanced Med Tech platforms like Auryon and AlphaVac, supported by active clinical trial validation. The core investment opportunity centers on scaling these differentiated proprietary technologies into large global markets while expanding insurance reimbursement coverage. However, key risks include ongoing bottom-line net losses, intense competition from well-capitalized medtech conglomerates, and execution pressures. The stock is best suited for growth-oriented investors willing to tolerate small-cap volatility while monitoring profitability progress and clinical trial milestones.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | While its Med Tech segment exhibits robust double-digit growth, overall company profitability remains under pressure. |
| Momentum investor | Strong fit while signal remains positive | Strong quarter-over-quarter revenue growth in core technology lines can attract positive short-term market momentum when technical trends are favorable. |
| Value investor | Weak fit | The lack of positive GAAP earnings makes traditional valuation metrics less applicable for value-oriented strategies. |
| Dividend investor | Weak fit | The company does not pay dividends, directing all earnings and cash toward business reinvestment. |
| Low-risk investor | Weak fit | Small-cap medical technology volatility and ongoing net losses present higher risk profiles unsuited for conservative investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Small-cap medical technology stocks frequently experience sharp price movements based on clinical trial updates and earnings reports. |
| Valuation risk | Medium / high | Valuations are sensitive to execution milestones given the current absence of consistent GAAP profitability. |
| Competition risk (large medtech conglomerates) | High | Competing against well-resourced giants like Boston Scientific and Medtronic threatens long-term market share gains. |
| Business quality | Medium | Proprietary medical devices offer strong gross margins, but bottom-line profitability remains constrained by high R&D and SG&A expenses. |
| Dividend income | Low / none | Income-focused investors receive zero yield since no cash dividends are distributed. |
| Execution risk | High | Successful scaling of newer platforms like Auryon and AlphaVac is critical to achieving sustained financial turnaround. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 499.19M USD | Price to earnings Ratio - | 1Y Target Price 19.75 |
Price to earnings Ratio - | 1Y Target Price 19.75 | ||
Volume (30-day avg) 865.5K shares | Beta 0.28 | 52 Weeks Range 9.39 - 16.29 | Updated Date 11/15/2026 |
52 Weeks Range 9.39 - 16.29 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.78 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Medical Instruments & Supplies
- BUY participation
- 60.0%
- Active BUY / eligible
- 3 / 5
- 30-Day BUY Count Change
- +1
Eligible universe: 5 stocks.
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Rolling Over
The price momentum is slowing down and beginning to turn downward.

Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -6.31% | Avg. Invested days 42 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Med Tech Segment | Revenues derived from advanced high-growth platforms including the Auryon atherectomy system and AlphaVac/AngioVac thrombectomy systems. | This is the primary growth engine driving double-digit percentage sales increases for the company. |
| Med Device Segment | Revenues from established product portfolios including peripheral vascular tools, vascular access ports, drainage catheters, and ablation systems. | Provides a steady base of recurring clinical product sales while higher-margin technologies scale up. |
| Geographic Operations | Direct and distributor-based sales generated primarily within the United States alongside international markets. | The vast majority of revenue originates domestically in the US healthcare market. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE 96.15 | Enterprise Value 459.43M | Price to Sales(TTM) 1.53 |
Enterprise Value 459.43M | Price to Sales(TTM) 1.53 | ||
Enterprise Value to Revenue 1.41 | Enterprise Value to EBITDA 120.9 | Shares Outstanding 42.05M | Shares Floating 32.76M |
Shares Outstanding 42.05M | Shares Floating 32.76M | ||
Percent Insiders 13.68 | Percent Institutions 91.75 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

